Rhabdomyosarcoma — Trials

Rhabdomyosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 74
Recruiting: 37
Ph III recruiting: 4
Growth YoY: —
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 25%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (22)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05304585	Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma	recruiting	Phase 3	205	Children's Oncology GroupNETWORK	4	Aug 25, 2026	clinicaltrials
NCT07466316	A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)	recruiting	Phase 3	342	Children's Oncology GroupNETWORK	2	Aug 25, 2026